Shares of Moderna, Inc. (NASDAQ: MRNA) moved higher in after-hours trading following a significant announcement regarding its clinical pipeline. The stock closed the regular session at $194.82, a gain of 6.98%, and edged 0.087% higher to $194.99 in after-hours trading.
The movement was driven by the company’s announcement that three abstracts on intismeran autogene, its investigational mRNA-based individualized neoantigen therapy, have been accepted for presentation at the European Society for Medical Oncology Congress 2026. The event is scheduled to take place in Madrid from October 23 to 27.
The lead abstract, selected for the Presidential Symposium, details data from the Phase 3 trial INTerpath-001. This trial is evaluating intismeran in combination with Merck & Co.’s (NYSE: MRK) pembrolizumab versus pembrolizumab alone. The study is focused on resected stage IIB-IV melanoma patients. Two additional poster presentations will present data regarding the therapy's application in pancreatic and early-stage non-small cell lung cancer.
According to data from Benzinga Pro, Moderna has a market capitalization of $77.78 billion. The stock is currently trading near its 52-week high of $195.71, having experienced a gain of 655.41% over the past 12 months. The Relative Strength Index (RSI) for the stock stands at 75.12, indicating strong momentum.
